MedTrace Logo

The Effect of Administration on N-Acetylcysteine on Serum Creatinine Levels in Patients With Chronic Kidney Disease

NCT00498342 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL

Last updated 2008-02-18

No results posted yet for this study

Summary

Primary outcome: Serum creatinine change at 4 hours and 48 hours following 4 doses of N-acetylcysteine (total 4800 mg) compared to baseline serum creatinine.

Secondary outcome: Serum Cystatin C change at 4 hours and 48 hours post 4 doses of N-acetylcysteine compared to baseline serum Cystatin C.

Conditions

Interventions

DRUG

N-acetylcysteine

Sponsors & Collaborators

  • FlowMedic

    collaborator INDUSTRY

  • University of Vermont

    lead OTHER

Principal Investigators

  • Richard J Solomon, M.D. · University of Vermont/Fletcher Allen Health Care,Inc.

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
89 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-06-30
Primary Completion
2008-01-31
Completion
2008-02-29

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00498342 on ClinicalTrials.gov